Last week, Boehringer Ingelheim announced that it had enrolled the first patient into its VOLTAIRE-X interchangeability study.  This Phase 3 study will investigate the interchangeability of BI’s adalimumab biosimilar candidate, BI 695501, and Humira^® in patients with moderate-to-severe chronic plaque psoriasis.  According to BI, results from this study are expected in the second half of 2019.